AGEN

Agenus
AGEN
Market cap $66.8M

2.83 USD

+0.07

2.54%

At close Dec 20, 4:00 PM EST

After hours

2.83

+0.00

0.00%

1 day

2.54%

5 days

-6.91%

1 month

5.99%

3 months

-51.54%

6 months

-79.15%

Year to date

-82.31%

1 year

-81.21%

5 years

-96.46%

10 years

-96.42%

About: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Employees: 389

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

762% more call options, than puts

Call options by funds: $11.2M | Put options by funds: $1.3M

41% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 22

10% more funds holding

Funds holding: 88 [Q2] → 97 (+9) [Q3]

8% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 24

4.66% less ownership

Funds ownership: 43.62% [Q2] → 38.96% (-4.66%) [Q3]

94% less capital invested

Capital invested by funds: $822M [Q2] → $45.7M (-$777M) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for AGEN.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about AGEN published over the past 30 days

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium. The conference will take place on January 23-25, 2025, in San Francisco, California. The presentations will showcase BOT/BAL's activity across three distinct co.

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. This initiative follows the successful closing of a $22 million mortgage secured by key real estate assets, providing the compan.

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing mortgage backed by its Berkeley-based Biologics CMC facility ("901 Heinz") and its 66-acre biomanufacturing-zoned property in Vacaville, California. Facilitated by L&L Capital, the transaction yields $20 million in net proceeds after closing costs and interest reserve, bolstering the company's cash p.

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Zacks Investment Research

Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Agenus (AGEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround

Agenus (AGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Agenus Inc. (NASDAQ:AGEN ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Garo Armen - Chairman and CEO Steven O'Day - CMO Robin Taylor - CCO Christine Klaskin - VP of Finance Conference Call Participants Emily Bodnar - H.C. Wainright Madeline Stone - William Blair Operator Good morning and welcome to Agenus' Third Quarter 2024 Conference Call and Webcast.

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Zacks Investment Research

Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates

Agenus (AGEN) came out with a quarterly loss of $3.17 per share versus the Zacks Consensus Estimate of a loss of $2.10. This compares to loss of $3.20 per share a year ago.

Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. “BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short,” said Garo Armen, Ph.D., Chairman and CEO of Agenus. “Its potential extends bey.

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D.,.

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

See News Rankings

Charts implemented using Lightweight Charts™